Medical condition
Heart Failure
Heart Failure is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- dronedarone (MULTAQ) Cardiovascular system (C01)
- dabigatran etexilate (DABIGATRAN ETEXILATE ACCORD) Blood and blood forming organs (B01)
- apixaban (ELIQUIS) Blood and blood forming organs (B01)
- dapagliflozin (FORXIGA) Alimentary tract and metabolism (A10)
- enalapril maleate (AQUMELDI) Cardiovascular system (C09)
- enoxaparin sodium (CLEXANE FORTE SAFETY-LOCK) Blood and blood forming organs (B01)
- rivaroxaban (APO-RIVAROXABAN) Blood and blood forming organs (B01)
- edoxaban (LIXIANA) Blood and blood forming organs (B01)
- ivabradine (APO-IVABRADINE) Cardiovascular system (C01)
- sacubitril (ENTRESTO) Cardiovascular system (C09)
- vericiguat (VERQUVO) Cardiovascular system (C01)
- empagliflozin (JARDIANCE) Alimentary tract and metabolism (A10)
Latest Heart Failure news
Innovative Heart Patch from Stem Cells: A Game Changer for Heart Failure
A groundbreaking heart patch developed from stem cells shows promise in revitalizing weakened hearts. This article explores its implications for the pharmaceutical industry.
Berlin Heals Reports Positive First-in-Human Results for Less Invasive Heart Failure Device in CMIC-III Study
Berlin Heals announces positive CMIC-III first-in-human study results showing improved heart function and quality of life with less invasive heart failure device.
FDA Approves MyoRepair: Breakthrough Therapy for Heart Failure
The FDA has approved MyoRepair, a groundbreaking therapy for heart failure, marking a significant advancement in treatment options for patients.
FDA Priority Review Granted to CardioGen's RevivCor for Heart Failure
CardioGen's RevivCor has received FDA Priority Review status for heart failure, signaling a potential breakthrough in treatment options for patients.